PNPLA3 and portal hypertension: Moreover, the PNPLA3 rs738409 G-allele (i.e., a well-established genetic risk factor for liver disease progression—as confirmed by our study—and HCC development) did not impact changes in surrogates of portal hypertension (PLT, LSM, VWF, and VITRO) and the development of clinical events (i.e., hepatic decompensation, HCC, and transplant-free mortality/liver-related transplant-free mortality) after the removal of the primary etiologic factor in a cohort of 346 patients.